These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25047443)

  • 1. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
    Park B
    Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.
    Sung B; Murakami A; Oyajobi BO; Aggarwal BB
    Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.
    Sung B; Cho SG; Liu M; Aggarwal BB
    Int J Cancer; 2011 Nov; 129(9):2062-72. PubMed ID: 21170936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
    Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
    Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse model.
    Huang J; Zhou L; Wu H; Pavlos N; Chim SM; Liu Q; Zhao J; Xue W; Tan RX; Ye J; Xu J; Ang ES; Feng H; Tickner J; Xu J; Ding Y
    Mol Cell Endocrinol; 2015 Jan; 399():346-53. PubMed ID: 25448849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
    Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
    Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Aggarwal BB
    Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.